Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TK-8001 first-in-human study in MAGE-A1-positive advanced solid tumors
NL-OMON53302Phase 2Withdrawn
- Sponsor
- T-knife Therapeutics
- Start
- May 2023
- Modality
- Cell Therapies, Gene Therapies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TK-8001 in Nonhematologic neoplasms and Non-hematologic malignancy, sponsored by T-knife Therapeutics. Primary endpoints: Incidence and grade of treatment-emergent adverse events and serious adverse events, Number and type of dose-limiting toxicities and 1 more. Planned start May 2023; status: withdrawn.
02
Drugs
TK-8001
03
Conditions
Nonhematologic neoplasmsNon-hematologic malignancy
Beyond the preview
Go deeper on NL-OMON53302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53302.